$PRCT

Templin Barry L sold $10K of PRCT

Templin Barry L (EVP, Chief Technology Officer) sold 358 shares of PROCEPT BioRobotics Corp (PRCT) at $28.48 on 2026-06-08.

Original reporting
SEC EDGAR · Templin Barry L
Published Jun 10, 2026, 8:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 8:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PRCT
Bearish
medium confidence
Mentioned
$PRCT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRCTBearishLow
01

Why it matters

The newest fact is the CTO’s open-market sale of 358 shares at $28.4790 on 2026-06-08, with holdings after the trade of 68,953 shares and no pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale as a sentiment datapoint, but the small dollar amount limits tradable impact absent other catalysts.

03

What to watch

The article provides only the sale details (size, price, holdings) and no context on compensation, tax obligations, or prior planned sales cadence.

Relevance 3/10Novelty 6/10Timing: filed 2026-06-10 for a sale dated 2026-06-08

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Procept BioRobotics (PRCT).

Company-level read

Ticker impact

$PRCTBearishMedium confidence
Context

Procept BioRobotics CTO sold 358 shares in an open-market transaction reported on SEC Form 4 (no 10b5-1 plan).

Expected impact

Low likelihood of a sustained price move; any reaction would likely be short-lived unless followed by additional insider selling or new company catalysts.

Evidence & confidence

The filing is primary-source (Form 4) and the sale is real, but the transaction value (~$10.2k) is small and does not indicate a corporate event or guidance change.

Market effects

No direct sector read-through; this is an individual insider transaction without disclosed operational/regulatory impact.

None indicated.

None indicated.

Counterpoint

Insider sales can be routine for diversification/taxes; the absence of a 10b5-1 plan does not necessarily imply bearish expectations.

Key entities

  • PROCEPT BioRobotics Corp

    Company whose insider transaction was disclosed via SEC Form 4.

  • Templin Barry L

    EVP, Chief Technology Officer who sold shares.

Related articles

Med

PROCEPT BioRobotics Corporation Q2 2026 Earnings Call Summary

Procept BioRobotics reported Q2 2026 revenue up 19% year over year to $94.5 million, citing HYDROS system demand and record ASPs, while U.S. procedures grew 21% but missed expectations due to softness in legacy AQUABEAM accounts. Full-year 2026 revenue guidance remains $390 million to $410 million; U.S. procedures guidance lowered to 54,000–56,000. Management expects positive adjusted EBITDA in Q4 2026 and ongoing HYDROS replacement cycle through 2027.

$PRCTMedAI 8/10

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline

The acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.

$PRCTMed

Evercore Initiates PROCEPT BioRobotics (PRCT) At “Outperform,” Cites Aquablation Growth Potential

PROCEPT BioRobotics (NASDAQ:PRCT) reported progress in its WATER IV prostate cancer program: enrollment completed for WATER IV RP (280 patients; Aquablation vs radical prostatectomy) with primary results expected at the AUA meeting in spring 2027, and FDA IDE approval for WATER IV AS (up to 333 patients; Aquablation vs active surveillance). Evercore ISI initiated coverage with an “Outperform” rating and $30 price target.